GSK ends early testing of GSK3965193 as hepatitis B strategy narrows
GSK has terminated the phase 1 trial of GSK3965193, a PAPD5/PAPD7 inhibitor that had been positioned as a next-generation approach to chronic hepatitis B. The decision closes the first-in-human study before the program could move from healthy-volunteer testing into patient cohorts designed to measure hepatitis B surface antigen reduction.
The timing is striking. On the same week that GSK secured FDA approval for bepirovirsen in chronic hepatitis B, the company quietly pulled one of the earlier pipeline assets that had been intended to extend its reach in the disease.
Why PAPD5/PAPD7 inhibition drew attention in chronic hepatitis B
GSK3965193 entered phase 1 development in 2022 as a first-in-human program. The trial was structured to begin in healthy participants before shifting into people living with chronic hepatitis B, where investigators planned to explore whether the molecule could lower hepatitis B virus surface antigen levels. In a disease defined by persistent viral persistence and immune evasion, a host-targeted mechanism such as PAPD5/PAPD7 inhibition carried a clear biological rationale: by disrupting pathways the virus depends on for maintaining its replication program, the therapy was meant to push treatment closer to a functional cure strategy rather than routine suppression alone.
That ambition made the program relevant even before any patient efficacy data emerged. Surface antigen remains one of the most closely watched readouts in hepatitis B drug development because it reflects how deeply a candidate can interfere with the virus’s persistence machinery. A phase 1 study is not meant to answer the full clinical question, but it does establish whether a mechanism can advance from theory into a tolerable human exposure window.
The trial never reached that second stage.
The registry update changed the picture before efficacy data arrived
The federal clinical trials registry now describes the study’s status as terminated after GSK made what it called a strategic decision to end it. A company spokesperson confirmed the termination. The registry update is the clearest public marker that development has stopped, even though GSK’s website still listed GSK3965193 in phase 1 at the time the article was published.
In practical terms, the termination means the program no longer appears headed toward the planned hepatitis B patient cohort. Healthy-volunteer safety and pharmacology work may still inform broader platform decisions, but without movement into infected participants, the candidate loses the chance to demonstrate whether PAPD5/PAPD7 inhibition can translate into antigen decline in the clinical setting that matters most.
Bepirovirsen’s approval sharpens GSK’s priorities
The pullback comes as GSK’s hepatitis B franchise has gained new weight through FDA approval of bepirovirsen, now marketed as Hibsago for adults with chronic hepatitis B who are receiving nucleos(t)ide analogue reverse transcriptase inhibitor therapy and do not have cirrhosis. The approval gives GSK a validated commercial and scientific anchor in a field where true functional cure remains difficult to achieve.
In that context, not every experimental asset carries equal strategic value. Companies often trim internal programs once a lead therapy secures regulatory traction, especially when the next candidate does not yet have patient efficacy data or a clear differentiation story. The public record here does not explain whether GSK3965193 fell because of safety, pharmacokinetics, feasibility, portfolio reprioritization, or a more fundamental lack of confidence in the mechanism. What is clear is that the clinical path forward has been cut off.
A shrinking internal pipeline around hepatitis B
GSK entered the year with several possible follow-ups to bepirovirsen in development. One of those, the TLR8 agonist GSK5251738, has already been scrapped. With GSK3965193 now terminated, the company’s remaining visible hepatitis B program appears to be the phase 2-stage GSK5637608, a hepatitis B virus-targeted siRNA.
The narrowing pipeline matters because hepatitis B drug development depends on combination logic. No single agent has yet solved the core problem of durable viral silencing and immune control across all patients. Different mechanisms are being explored to attack distinct nodes in the viral life cycle: one drug may suppress viral protein production, another may enhance innate immune activation, and another may interfere with host factors that support persistence. When a program like GSK3965193 disappears before proof of concept, it removes one of the possible layers from that combination future.
What the termination means for the field
The end of this trial does not overturn the larger concept behind PAPD5/PAPD7 inhibition, but it does remove one clinical test of that idea from the hepatitis B pipeline. First-in-human programs are meant to identify whether a target can survive exposure, tolerability, and early pharmacodynamic scrutiny. Once a company stops a study at this stage, the burden shifts to other molecules in the class, or to other mechanisms entirely, to prove whether the biology is worth pursuing in chronic hepatitis B.
For clinicians and drug developers, the more consequential point is the widening gap between regulatory success for one agent and the attrition of adjacent programs. Bepirovirsen’s approval validates GSK’s commitment to the disease, yet it also appears to have coincided with a more selective internal portfolio. The company has not clarified whether GSK3965193 is permanently abandoned or whether it might reappear in some altered form. For now, the public development path is closed.
No efficacy results were released from the terminated study, and no patient-level hepatitis B data from the candidate were provided. The unanswered question for the field is not whether chronic hepatitis B remains a high-priority therapeutic target; it clearly does. The open question is which mechanisms will survive the next wave of triage and which will be left behind before they ever reach the clinic.